Clinical trial NCT02042885: A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer
Official title: A Two-part Phase 1/2a, Open-label, Dose Escalation Study to Evaluate the Tolerability and Preliminary Antitumour Activity of OPB-111001 in Patients With Advanced Cancers That Are Poorly Responsive to Standard Anticancer Treatment
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: Prostate Cancer
Salivary Gland Cancer
Endometrial Cancer
Squamous Cell Carcinoma of the Cervix
Breast Cancer
Ovarian Cancer
Keywords: Prostate cancer
Lead sponsor: Otsuka Novel Products GmbH
Sponsor class: INDUSTRY
First posted: 2014-01-23
Enrollment: 79
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the tolerability profile of OPB-111001 and to determine the most suitable dose of OPB-111001 in patients with advanced cancer


Eligibility criteria: Inclusion Criteria:

* ≥ 18 years of age
* Patients with prostate cancer that is recurrent or did not respond to previous hormone therapy and/or who have exhausted standard treatment options.

For the dose escalation parts only:

Patients who have exhausted standard treatment options with recurrent or refractory cancer (ovarian cancer, cervical squamous cell carcinoma, breast cancer, salivary gland cancer, endometrial cancer)

* Histologically or cytologically documented diagnosis of cancer
* Measurable disease according to RECIST Version 1.1 or for prostate cancer also evaluable disease according to Prostate Cancer Working Group 2 (PCWG2) eligibility criteria or for ovarian cancer also evaluable disease (non-measurable) according to Gynaecologic Cancer Intergroup (GCIG) criteria
* Absolute neutrophil count ≥1.5 (1500/mm3) and platelets ≥100 × 109/L (without platelet transfusion within the last 4 weeks before first study drug administration), and haemoglobin ≥9 g/dL at Screening
* Alanine aminotransferase and aspartate aminotransferase ≤2.5 × the upper limit of normal (ULN), Total bilirubin ≤1.5 × ULN (exception: patients with liver metastasis are allowed to have aspartate aminotransferase ≤5 × ULN and alanine aminotransferase ≤5 × ULN) at screening
* Albumin ≥26 g/L at Screening

Exclusion Criteria:

* Concurrent prior treatment-related toxicity of Grade 2 or higher. Exception: any toxicity that is in the view of the investigator not a clinically significant safety risk for Investigational medicinal product (IMP) administration.
* Previous treatment with cytotoxic chemotherapy or other anticancer therapy within 4 weeks before the first dosing with study drug (at least 6 weeks for mitoxantrone, nitrosurea, and bicalutamide).
* Treatment with systemic glucocorticosteroids of more than a 2 mg dexamethasone equivalent per day or in cases of treatment with ≤2 mg dexamethasone equivalent per day:

  1. Dosing was changed within 6 weeks before Screening or
  2. The patient's cancer is responding to glucocorticosteroid intake
* Radiation therapy within 4 weeks prior to the first dosing with IMP.
* Treatment with a systemic IMP in a clinical trial within 28 days before the Screening Visit.
* Current or past history of clinically significant gastrointestinal disease or major gastrointestinal surgery, malabsorption syndrome, or other conditions that could interfere with enteral absorption.
* Concurrent clinically significant unrelated systemic illness (e.g., serious infection) or significant pulmonary, hepatic, or other organ dysfunction that would compromise the patient's ability to tolerate study treatment or would likely interfere with study procedures or results.

Primary outcomes:
measure: Maximum tolerated dose / Recommended Phase 2 dose; Tolerability
timeFrame: after 2 or 6 weeks depending on study part; continously
Secondary outcomes:
measure: Pharmacokinetic parameters for OPB-111001 and its metabolites
timeFrame: repeatedly until end of study (average of 3 months assumed)
measure: Assessment of antitumor activity as defined by Response Evaluation Criteria in Solid Tumours (RECIST)
timeFrame: repeatedly every 8th week until end of study (average of 3 months assumed)
measure: Prostate-specific antigen (PSA) response in patients with prostate cancer
timeFrame: repeatedly (Cycle 1 to 3 on Day 1, then every 4th week) until end of study (average of 3 months assumed)
measure: Cancer antigen 125 (CA 125) response in patients with ovarian cancer
timeFrame: repeatedly (Cycle 1 to 3 on Day 1, then every 4th week) until end of study (average of 3 months assumed)
measure: Time to treatment failure
timeFrame: At end of study (after average of 3 months assumed)
Other outcomes:
Locations:
city: London, Sutton
country: United Kingdom
facility: The Institute of Cancer Research, Royal Marsden NHS Foundation Trust
state: Surrey
city: London
country: United Kingdom
facility: NIHR/Wellcome Trust Imperial CRF/Imperial College Healthcare NHS Trust, Imperial Centre for Translational and Experimental Medicine (L-Block), Hammersmith Hospital
Study officials:
affiliation: The Institute of Cancer Research, Royal Marsden NHS Foundation Trust London United Kingdom
name: Johann De Bono, Prof. Dr.
role: PRINCIPAL_INVESTIGATOR
affiliation: NIHR/Wellcome Trust Imperial CRF, Imperial College Healthcare NHS Trust, Imperial Center for Translational and Experimental Medicine (L-Block), Hammersmith Hospital London, United Kingdom
name: Sarah Blagden, Dr.
role: PRINCIPAL_INVESTIGATOR
References: